Upgrade to SI Premium - Free Trial

Travere Therapeutics (TVTX)

46.18 +0.98 (2.17%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Travere presents long-term FILSPARI data at European kidney conference June 4, 2026 10:09 AM - StreetInsider Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress June 4, 2026 10:09 AM - BizWire Travere Therapeutics (TVTX) PT Raised to $62 at Citi June 3, 2026 12:53 PM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $67 at H.C. Wainwright June 2, 2026 11:38 AM - StreetInsider Form 8-K Travere Therapeutics, For: Jun 01 June 2, 2026 7:05 AM - SEC Filing Travere licenses BTK inhibitor from Everest for rare kidney diseases June 2, 2026 7:01 AM - StreetInsider Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases June 2, 2026 7:01 AM - BizWire Travere receives patent allowance for FILSPARI use in kidney disease May 27, 2026 4:05 PM - StreetInsider Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy May 27, 2026 4:05 PM - BizWire Form 4 Travere Therapeutics, For: May 19 Filed by: Williams Brinkley Ruth May 21, 2026 5:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Meckler Jeffrey A May 21, 2026 5:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Orwin John A May 21, 2026 5:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Squarer Ron May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Poole Sandra May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Baynes Roy D. May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Bruhn Suzanne Louise May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: LYONS GARY A May 21, 2026 5:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 19 Filed by: Coughlin Timothy May 21, 2026 5:00 PM - SEC Filing Form 8-K Travere Therapeutics, For: May 19 May 21, 2026 4:08 PM - SEC Filing Form 4 Travere Therapeutics, For: May 15 Filed by: Coughlin Timothy May 19, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Coughlin Timothy May 15, 2026 12:51 PM - SEC Filing Form SCHEDULE 13G Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC May 15, 2026 11:17 AM - SEC Filing Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 12, 2026 5:00 PM - BizWire Form 8-K Travere Therapeutics, For: May 06 May 11, 2026 5:10 PM - SEC Filing Travere Therapeutics to Participate at Upcoming Investor Conferences May 7, 2026 4:30 PM - BizWire Form 424B5 Travere Therapeutics, May 7, 2026 4:19 PM - SEC Filing Form 305B2 Travere Therapeutics, May 7, 2026 4:02 PM - SEC Filing Form FWP Travere Therapeutics, Filed by: Travere Therapeutics, Inc. May 7, 2026 6:08 AM - SEC Filing Travere prices $475 million convertible notes to refinance 2029 debt May 6, 2026 10:28 PM - StreetInsider Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes May 6, 2026 10:28 PM - BizWire Form 4 Travere Therapeutics, For: May 05 Filed by: Baynes Roy D. May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Meckler Jeffrey A May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: REED ELIZABETH E May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: ROTE WILLIAM E. May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Inrig Jula May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Heerma Peter May 6, 2026 8:01 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Cline Christopher R. May 6, 2026 8:00 PM - SEC Filing Form 4 Travere Therapeutics, For: May 04 Filed by: Dube Eric M May 6, 2026 8:00 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Cline Christopher R. May 6, 2026 4:04 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E May 6, 2026 4:03 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula May 6, 2026 4:03 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M May 6, 2026 9:55 AM - SEC Filing Form 144 Travere Therapeutics, Filed by: ROTE WILLIAM E. May 6, 2026 9:37 AM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $50 at Wells Fargo May 6, 2026 8:44 AM - StreetInsider Form 144 Travere Therapeutics, Filed by: Cline Christopher R. May 5, 2026 7:48 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E May 5, 2026 7:32 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula May 5, 2026 7:32 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Heerma Peter May 5, 2026 7:32 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Baynes Roy D. May 5, 2026 4:53 PM - SEC Filing Form 424B5 Travere Therapeutics, May 5, 2026 4:05 PM - SEC Filing Travere plans $400 million convertible notes offering to refinance debt May 5, 2026 4:01 PM - StreetInsider Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes May 5, 2026 4:01 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $60 at TD Cowen May 5, 2026 8:54 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $54 at Jefferies May 5, 2026 7:42 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $57 at H.C. Wainwright May 5, 2026 7:34 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $59 at Citi May 5, 2026 4:03 AM - StreetInsider Form 10-Q Travere Therapeutics, For: Mar 31 May 4, 2026 4:46 PM - SEC Filing Form 4 Travere Therapeutics, For: May 01 Filed by: Baynes Roy D. May 4, 2026 4:27 PM - SEC Filing Form 8-K Travere Therapeutics, For: May 04 May 4, 2026 4:06 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E May 4, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Meckler Jeffrey A May 4, 2026 4:04 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula May 4, 2026 4:04 PM - SEC Filing Travere Therapeutics (TVTX) Misses Q1 EPS by 17c May 4, 2026 4:02 PM - StreetInsider Travere Therapeutics Reports First Quarter 2026 Financial Results May 4, 2026 4:01 PM - BizWire Form 144 Travere Therapeutics, Filed by: Baynes Roy D. May 1, 2026 4:16 PM - SEC Filing Form SCHEDULE 13G Travere Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 2:08 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $50 at BofA Securities April 30, 2026 9:10 AM - StreetInsider Travere Therapeutics to Report First Quarter 2026 Financial Results April 27, 2026 4:30 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $50 at Jefferies April 24, 2026 8:00 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $56 at Guggenheim April 24, 2026 6:40 AM - StreetInsider Form 4 Travere Therapeutics, For: Apr 22 Filed by: ROTE WILLIAM E. April 23, 2026 7:21 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: ROTE WILLIAM E. April 22, 2026 10:36 AM - SEC Filing Form 4 Travere Therapeutics, For: Apr 14 Filed by: LYONS GARY A April 16, 2026 4:05 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 14 Filed by: Baynes Roy D. April 16, 2026 4:05 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 14 Filed by: Calvin Sandra April 16, 2026 4:05 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 13 Filed by: Heerma Peter April 15, 2026 9:49 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 13 Filed by: ROTE WILLIAM E. April 15, 2026 9:49 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 13 Filed by: Dube Eric M April 15, 2026 9:48 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 13 Filed by: REED ELIZABETH E April 15, 2026 9:47 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 13 Filed by: Cline Christopher R. April 15, 2026 9:47 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 13 Filed by: Inrig Jula April 15, 2026 9:47 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M April 15, 2026 4:17 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E April 15, 2026 4:16 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Cline Christopher R. April 15, 2026 4:15 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula April 15, 2026 4:13 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $51 at JPMorgan April 15, 2026 8:40 AM - StreetInsider Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E April 14, 2026 9:17 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula April 14, 2026 8:54 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Heerma Peter April 14, 2026 8:47 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Cline Christopher R. April 14, 2026 8:41 PM - SEC Filing Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 14, 2026 5:00 PM - BizWire Form 144 Travere Therapeutics, Filed by: LYONS GARY A April 14, 2026 4:28 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Cline Christopher R. April 14, 2026 4:20 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E April 14, 2026 4:19 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Baynes Roy D. April 14, 2026 4:09 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Calvin Sandra April 14, 2026 4:03 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $43 at Stifel April 14, 2026 3:07 PM - StreetInsider Piper Sandler Upgrades Travere Therapeutics (TVTX) to Overweight April 14, 2026 11:10 AM - StreetInsider Increasing unusual put option volume: TVTX ASTX BW NUAI SCO CPB BNO LUMN LWLG RVMD AEHR KMX April 14, 2026 10:45 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $49 at BofA Securities April 14, 2026 9:13 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $44 at Wedbush April 14, 2026 8:52 AM - StreetInsider Travere Therapeutics (TVTX) Reiterated at Overweight by Cantor Fitzgerald on FSGS Approval April 14, 2026 7:07 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $54 at Guggenheim April 14, 2026 7:04 AM - StreetInsider FDA approves FILSPARI for rare kidney disease FSGS April 14, 2026 7:00 AM - StreetInsider Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS April 14, 2026 7:00 AM - Globe NewsWire Travere Therapeutics (TVTX) PT Raised to $56 at Canaccord April 14, 2026 7:00 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX) April 14, 2026 6:47 AM - StreetInsider Form 8-K Travere Therapeutics, For: Apr 13 April 14, 2026 6:03 AM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $53 at Citi April 14, 2026 5:02 AM - StreetInsider Form 144 Travere Therapeutics, Filed by: Cline Christopher R. April 13, 2026 8:11 PM - SEC Filing FDA approves Travere's FILSPARI as first treatment for FSGS April 13, 2026 6:16 PM - StreetInsider Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS April 13, 2026 6:16 PM - BizWire Form 4 Travere Therapeutics, For: Apr 06 Filed by: Baynes Roy D. April 7, 2026 6:17 PM - SEC Filing Form ARS Travere Therapeutics, For: Dec 31 April 6, 2026 4:12 PM - SEC Filing Form DEFA14A Travere Therapeutics, April 6, 2026 4:09 PM - SEC Filing Form DEF 14A Travere Therapeutics, For: May 19 April 6, 2026 4:08 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Baynes Roy D. April 6, 2026 4:06 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 01 Filed by: REED ELIZABETH E April 2, 2026 5:55 PM - SEC Filing Form 4 Travere Therapeutics, For: Apr 01 Filed by: Dube Eric M April 2, 2026 5:55 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M April 1, 2026 4:14 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E April 1, 2026 4:07 PM - SEC Filing Form SCHEDULE 13G/A Travere Therapeutics, Filed by: VANGUARD GROUP INC March 27, 2026 1:34 PM - SEC Filing Travere Therapeutics (TVTX) PT Lowered to $41 at JPMorgan March 25, 2026 8:41 AM - StreetInsider Citi Adjusts Catalyst Call List March 24, 2026 5:03 AM - StreetInsider Form 4 Travere Therapeutics, For: Mar 16 Filed by: REED ELIZABETH E March 18, 2026 4:06 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E March 16, 2026 4:22 PM - SEC Filing Full Article List